{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:10:58Z","timestamp":1778170258666,"version":"3.51.4"},"reference-count":43,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"unspecified","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Gansu Province Traditional Chinese Medicine Research Project","award":["GZKZ-2024-29"],"award-info":[{"award-number":["GZKZ-2024-29"]}]},{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260325"],"award-info":[{"award-number":["82260325"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Fundamental Research Funds for the Central Universities of Lanzhou University","award":["lzujbky-2024-oy03"],"award-info":[{"award-number":["lzujbky-2024-oy03"]}]},{"name":"Key Research Projects in the Health Sector of Gansu Province","award":["GSWSDZ2025-06"],"award-info":[{"award-number":["GSWSDZ2025-06"]}]},{"name":"the Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital","award":["CY2024-MS-A03"],"award-info":[{"award-number":["CY2024-MS-A03"]}]},{"name":"the Natural Science Foundation of Gansu Province","award":["24JRRA923"],"award-info":[{"award-number":["24JRRA923"]}]},{"name":"the Natural Science Foundation of Gansu Province","award":["25YFFA055"],"award-info":[{"award-number":["25YFFA055"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,4,7]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Nerandomilast, a selective phosphodiesterase 4B (PDE4B) inhibitor, has been extensively investigated for the treatment of pulmonary fibrosis; however, its therapeutic potential and mechanisms of action in idiopathic inflammatory myopathies-associated interstitial lung disease (IIM-ILD) remain to be elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A myositis-associated ILD mouse model was treated with nerandomilast (BI 1015550), and lung pathology was assessed histologically. Human lung microvascular endothelial cells-5a were stimulated with neutrophil extracellular traps (NETs) to induce endothelial\u2013mesenchymal transition (EndMT). Western blotting, immunofluorescence, qPCR and ELISA were employed to analyse pathways and cytokines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PDE4B was upregulated in the lungs of patients with IIM-ILD and in mice. Treatment with BI 1015550 significantly reduced lung inflammation and fibrosis scores, decreased inflammatory cytokines in bronchoalveolar lavage fluid and serum, alleviated muscle inflammation and lowered kinase activity without evident hepatorenal toxicity. Immunofluorescence and immunohistochemistry revealed diminished NET markers, reduced inflammatory cell infiltration (CD3, CD11b, F4\/80), suppression of EndMT, downregulation of Ras homolog family member A (RhoA) and inhibition of key fibrotic pathways: phosphorylated phosphoinositide 3-kinase (P-PI3K), phosphorylated protein kinase B (P-AKT), phosphorylated p38 mitogen-activated protein kinase (P-P38), phosphorylated extracellular signal-regulated kinase (P-ERK), phosphorylated nuclear factor kappa-B (P-NF-\u03baB). In vitro, BI 1015550 inhibited phorbol 12-myristate 13-acetate-induced neutrophil extracellular trap formation (NETosis) and EndMT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nerandomilast alleviates IIM-ILD by inhibiting NET formation and suppressing EndMT in lung microvascular endothelial cells, potentially through non-Smad signalling pathway modulation and cAMP\u2013PKA\u2013RhoA pathway activation. These findings suggest that the specific inhibition of PDE4B is a potential therapeutic approach for IIM-ILD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006683","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:15:26Z","timestamp":1778166926000},"page":"e006683","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Nerandomilast alleviates myositis-associated interstitial lung disease by modulating the non-Smad signalling pathway and activating the cAMP\u2013PKA\u2013RhoA pathway"],"prefix":"10.1136","volume":"12","author":[{"given":"Xi","family":"Cui","sequence":"first","affiliation":[{"name":"The Second Clinical Medical School, Lanzhou University, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical School, Lanzhou University, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chai","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical School, Lanzhou University, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical School, Lanzhou University, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Guo","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical School, Lanzhou University, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-2225","authenticated-orcid":false,"given":"Jiarui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-1431","authenticated-orcid":false,"given":"Sigong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, China"},{"name":"Department of Rheumatology, Lanzhou University Second Hospital, Lanzhou, China"},{"name":"Gansu Province Clinical Research Center for Rheumatology, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026050708151764000_12.2.e006683.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.01.031"},{"key":"2026050708151764000_12.2.e006683.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-020-00383-w"},{"key":"2026050708151764000_12.2.e006683.3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/1744666X.2018.1411190","article-title":"Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review","volume":"14","author":"Atzeni","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2026050708151764000_12.2.e006683.4","doi-asserted-by":"crossref","first-page":"2416840","DOI":"10.1016\/j.pulmoe.2023.11.007","article-title":"Early detection of interstitial lung disease in rheumatic diseases: A joint statement from the Portuguese Pulmonology Society, the Portuguese Rheumatology Society, and the Portuguese Radiology and Nuclear Medicine Society","volume":"31","author":"Morais","year":"2025","journal-title":"Pulmonology"},{"key":"2026050708151764000_12.2.e006683.5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2026050708151764000_12.2.e006683.6","doi-asserted-by":"crossref","DOI":"10.1093\/cei\/uxaf019","article-title":"Pirfenidone alleviates interstitial lung disease in mice by inhibiting neutrophil extracellular trap formation and NLRP3 inflammasome activation","volume":"219","author":"Su","year":"2025","journal-title":"Clin Exp Immunol"},{"key":"2026050708151764000_12.2.e006683.7","doi-asserted-by":"crossref","first-page":"114144","DOI":"10.1016\/j.intimp.2025.114144","article-title":"cGAS-STING mediates neutrophil extracellular traps-induced EMT in myositis-associated interstitial lung disease: STING as a potential therapeutic target","volume":"149","author":"Feng","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"2026050708151764000_12.2.e006683.8","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1007\/s10753-024-02220-1","article-title":"Colchicine Alleviates Interstitial Lung Disease in an Experimental Autoimmune Myositis Murine Model by Inhibiting the Formation of Neutrophil Extracellular Traps","volume":"48","author":"Li","year":"2025","journal-title":"Inflammation"},{"key":"2026050708151764000_12.2.e006683.9","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3390\/diagnostics12082028","article-title":"Interstitial Lung Fibrosis Following COVID-19 Pneumonia","volume":"12","author":"Lazar","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2026050708151764000_12.2.e006683.10","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211037519","article-title":"Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders","volume":"13","author":"Panagopoulos","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026050708151764000_12.2.e006683.11","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0206-2022","article-title":"Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis","volume":"32","author":"Kolb","year":"2023","journal-title":"Eur Respir Rev"},{"key":"2026050708151764000_12.2.e006683.12","doi-asserted-by":"crossref","first-page":"1111393","DOI":"10.3389\/fphar.2023.1111393","article-title":"Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026050708151764000_12.2.e006683.13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004704","article-title":"Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases","volume":"10","author":"Aringer","year":"2024","journal-title":"RMD Open"},{"key":"2026050708151764000_12.2.e006683.14","first-page":"119","article-title":"Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases","volume":"43","author":"Castelino","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"2026050708151764000_12.2.e006683.15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00123","article-title":"The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases","volume":"7","author":"Raker","year":"2016","journal-title":"Front Immunol"},{"key":"2026050708151764000_12.2.e006683.16","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1053"},{"key":"2026050708151764000_12.2.e006683.17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.982130"},{"key":"2026050708151764000_12.2.e006683.18","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in Patients with Progressive Pulmonary Fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"key":"2026050708151764000_12.2.e006683.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468"},{"key":"2026050708151764000_12.2.e006683.20","doi-asserted-by":"crossref","DOI":"10.1093\/cei\/uxae106","article-title":"A novel mouse model of myositis-associated interstitial lung disease was established by using TLR9 agonist combined with muscle homogenate","volume":"219","author":"Bai","year":"2025","journal-title":"Clin Exp Immunol"},{"key":"2026050708151764000_12.2.e006683.21","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s10753-024-02153-9","article-title":"Nerandomilast Improves Bleomycin-Induced Systemic Sclerosis-Associated Interstitial Lung Disease in Mice by Regulating the TGF-\u03b21 Pathway","volume":"48","author":"Liu","year":"2025","journal-title":"Inflammation"},{"key":"2026050708151764000_12.2.e006683.22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/annrheumdis-2012-eular.2219","article-title":"THU0254\u2005Correlation between muscle pathology findings and clinical variables in patients with inflammatory myositis","volume":"71","author":"Wangkaew","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026050708151764000_12.2.e006683.23","doi-asserted-by":"crossref","first-page":"106278","DOI":"10.1016\/j.bioorg.2022.106278","article-title":"Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement","volume":"130","author":"Wei","year":"2023","journal-title":"Bioorg Chem"},{"key":"2026050708151764000_12.2.e006683.24","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13753","article-title":"Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury","volume":"6","author":"Sisson","year":"2018","journal-title":"Physiol Rep"},{"key":"2026050708151764000_12.2.e006683.25","article-title":"The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages","volume":"28","author":"Matsuhira","year":"2021","journal-title":"Biochem Biophys Rep"},{"key":"2026050708151764000_12.2.e006683.26","doi-asserted-by":"crossref","first-page":"173508","DOI":"10.1016\/j.ejphar.2020.173508","article-title":"A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung","volume":"885","author":"Matsuhira","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2026050708151764000_12.2.e006683.27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/14397595.2016.1179861","article-title":"Abnormally increased low-density granulocytes in peripheral blood mononuclear cells are associated with interstitial lung disease in dermatomyositis","volume":"27","author":"Zhang","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2026050708151764000_12.2.e006683.28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/cei.12319","article-title":"Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications","volume":"177","author":"Zhang","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2026050708151764000_12.2.e006683.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.02.002"},{"key":"2026050708151764000_12.2.e006683.30","doi-asserted-by":"crossref","first-page":"115431","DOI":"10.1016\/j.intimp.2025.115431","article-title":"Neutrophil extracellular traps mediate macrophage polarization and pyroptosis through the TLR9-NF-\u03baB\/AIM2 pathway exacerbating myositis-associated interstitial lung disease","volume":"165","author":"Cui","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"2026050708151764000_12.2.e006683.31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaut.2016.12.003","article-title":"The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis","volume":"78","author":"Lu","year":"2017","journal-title":"J Autoimmun"},{"key":"2026050708151764000_12.2.e006683.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120590"},{"key":"2026050708151764000_12.2.e006683.33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048"},{"key":"2026050708151764000_12.2.e006683.34","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxae028"},{"key":"2026050708151764000_12.2.e006683.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.07.008"},{"key":"2026050708151764000_12.2.e006683.36","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-6-128","article-title":"Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration","volume":"6","author":"Pullamsetti","year":"2005","journal-title":"Respir Res"},{"key":"2026050708151764000_12.2.e006683.37","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.apsb.2024.01.012","article-title":"Endothelial phosphodiesterase 4B inactivation ameliorates endothelial-to-mesenchymal transition and pulmonary hypertension","volume":"14","author":"Xing","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"2026050708151764000_12.2.e006683.38","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.003707"},{"key":"2026050708151764000_12.2.e006683.39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature01148","article-title":"Rho GTPases in cell biology","volume":"420","author":"Etienne-Manneville","year":"2002","journal-title":"Nature New Biol"},{"key":"2026050708151764000_12.2.e006683.40","first-page":"2095","article-title":"Fluvastatin protects myocardial cells in mice with acute myocardial infarction through inhibiting RhoA\/ROCK pathway","volume":"19","author":"Yi","year":"2020","journal-title":"Exp Ther Med"},{"key":"2026050708151764000_12.2.e006683.41","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2787-y"},{"key":"2026050708151764000_12.2.e006683.42","doi-asserted-by":"crossref","DOI":"10.1002\/phy2.105","article-title":"Activation of RhoA\/Rho-kinase pathway accounts for pulmonary endothelial dysfunction in patients with chronic obstructive pulmonary disease","volume":"1","author":"Bei","year":"2013","journal-title":"Physiol Rep"},{"key":"2026050708151764000_12.2.e006683.43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105497","article-title":"From membrane to nucleus: A three-wave hypothesis of cAMP signaling","volume":"300","author":"Pizzoni","year":"2024","journal-title":"J Biol Chem"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:15:30Z","timestamp":1778166930000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,7]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/rmdopen-2025-006683"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006683","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}